INDICATIONS & USAGE SECTION.

INDICATIONS AND USAGE:. This product is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, xerosis, ichthyosis, skin cracks and fissures, dermatitis, eczema, psoriasis, keratoses and calluses.

INFORMATION FOR PATIENTS SECTION.

Information for Patients:. Patients should discontinue the use of this product if the condition becomes worse or if rash develops in the area being treated or elsewhere. Avoid contact with eyes, lips and mucous membranes.Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on this product to date. Studies on reproduction and fertility also have not been performed.

NURSING MOTHERS SECTION.

Nursing Mothers:. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to nursing woman.

PREGNANCY SECTION.

Pregnancy:. Category C.Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to pregnant woman. This product should be used by pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

WARNINGS SECTION.

WARNINGS:. KEEP OUT OF REACH OF CHILDREN. PRECAUTIONS: FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. General: This product is to be used as directed by physician and should not be used to treat any condition other than that for which it was prescribed. If redness or irritation occurs, discontinue use and consult physician.

ADVERSE REACTIONS SECTION.

ADVERSE REACTIONS:. Transient stinging, burning, itching or irritation may occur and normally disappear upon discontinuing the use of this product. CALL YOUR DOCTOR ABOUT SIDE EFFECTS. Call your doctor about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

CLINICAL PHARMACOLOGY SECTION.

CLINICAL PHARMACOLOGY:. Urea gently dissolves the intercellular matrix which results in loosening the horny layer of skin and shedding scaly skin at regular intervals, thereby softening hyperkeratotic areas of the skin.Pharmacokinetics: The mechanism of action of topically applied urea is not yet known.

CONTRAINDICATIONS SECTION.

CONTRAINDICATIONS:. This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

DESCRIPTION SECTION.

DESCRIPTION:. Protexa Cream (42% Urea) is keratolytic emollient which is gentle, yet potent, tissue softener for nails and/or skin. Each gram contains 42% Urea, Water, Prunus Amygdalus Dulcis (Sweet Almond) Oil, Glycerin, Ceteary Alcohol, Polysorbate 60, Dimethicone, C12-15 Alkyl Benzoate, Glyceryl Stearate, PEG-100 Stearate, Propylene Glycol, Aloe Barbadensis Leaf Juice Powder, Phenoxyethanol, Ethylhexylglycerin, Xanthan Gum, Citric Acid. Urea Urea is diamide of carbonic acid with the following chemical structure:. chemicalstructure.

DOSAGE & ADMINISTRATION SECTION.

DOSAGE AND ADMINISTRATION:. Apply to affected area(s) twice per day or as directed by physician. Rub in until completely absorbed.

HOW SUPPLIED SECTION.

HOW SUPPLIED:. Protexa Cream (42% Urea) is available as follows: 45g container, NDC 69336-810-45KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under physicians supervision. There are no implied or explicit claims on the therapeutic equivalence.Store at 20C to 25C (68F to 77F), excursions permitted between 15C to 30C (between 59F to 86F). Brief exposure to temperatures up to 40C (104F) may be tolerated provided the mean kinetic temperature does not exceed 25C (77F); however, such exposure should be minimized. Protect from freezing and excessive heat. Keep bottle tightly closed.Distributed By:Sterling-Knight Pharmaceuticals, LLCRipley, MS 38663Item: 810 Rev. 09/19.